Numbers first: 8 mg · retatrutide.
I would rather over-plan the first cycle and simplify later.
I am prepared to do the work if someone can tell me which work matters.
How do I make this decision on evidence rather than on feel?
8 mg a week is 1.143 mg a day averaged out and 416 mg over a year — but "defensible" is not a property of the number, it is a property of where the number came from. A maintenance dose is defensible when a trial randomised people to it and reported what happened, and indefensible when it was arrived at by interpolation between two doses that were studied. So the question to ask of 8 mg is which arm it corresponds to: if a programme ran 8 mg as a maintenance level, there is an efficacy figure, a tolerability figure and a discontinuation rate attached to it. If it sits between two studied levels, everything said about it is extrapolation, and the burden of that is on whoever proposed it. The other half of the arithmetic is supply: at 8 mg a week a 10 mg vial is 1.25 weeks and you will need about 42 of them a year, which is worth knowing before the dose is settled rather than after. Maintenance doses are set by a prescriber against an individual; nothing here is medical advice.
The relevant observation is that maintenance frequently requires less exposure than the loss phase did, and the trials suggest it rather than establish it.
A downward search proceeds one step at a time with at least eight weeks at each level, because a weekly agent takes four to five weeks to reach the new steady state and then needs time for the trend to be readable.
| Week | Fraction of steady state | Trough as × dose |
|---|---|---|
| 1 | 50 % | 0.50 |
| 2 | 75 % | 0.75 |
| 3 | 88 % | 0.88 |
| 4 | 94 % | 0.94 |
| 5 | 97 % | 0.97 |
| 6 | 98 % | 0.98 |
This is why a four-week step interval is approximately, but not exactly, steady state.
Glycaemic maintenance has a faster and cleaner signal than weight maintenance, particularly with continuous monitoring, which makes the downward search more tractable when glycaemia is the endpoint.
STEP-4 and SURMOUNT-4 evaluated withdrawal rather than dose reduction, which is the limit of the direct evidence on this question.
Inference from the withdrawal trials to dose reduction is inference and should be labelled as such.
Glycaemic maintenance gives a faster signal than weight maintenance.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThis is a question the trial programmes answered only partially, and it is worth saying which parts are evidenced.
Maintenance and loss are different endpoints. Loss requires a sustained energy deficit; maintenance requires only that the counter-regulatory drive is offset, and that may need less exposure.
The maintenance dose is not necessarily the same a year later, since the counter-regulatory response attenuates slowly if at all.
The counter-regulatory hormonal response to weight loss persists for at least a year after the loss, which is the physiological reason maintenance needs something rather than nothing.
The withdrawal trials answer stopping, not reducing. Different questions.
The short version: reach a working dose, hold it, and then consider whether less would hold it just as well.
Weight is a noisy signal. A rolling four-week average is the instrument; single weigh-ins after a dose reduction will show nothing interpretable.
If the result deteriorates on a lower dose, returning to the previous one is straightforward and does not require re-titration from the bottom provided the gap has been short.
Dose-response for weight in the trial programmes was real but flattening at the upper end, which is consistent with a lower maintenance requirement.
A noisy weight signal makes premature conclusions easy, in both directions.
Search downward, one step, eight weeks each, on a rolling average.
Answering this needs the reason for the current dose, since a dose chosen for loss and a dose chosen for maintenance are different decisions.
Gastrointestinal tolerability generally improves on a reduced dose, which is a genuine quality-of-life argument for the search rather than only a cost one.
Gastrointestinal adverse event rates in the trials are dose-related, which supports the tolerability argument for the lowest effective dose.
The lowest dose that holds the result is the answer, and it is individual.
Answer first: the maintenance dose is the lowest one that holds the result, and finding it is a downward search rather than an upward one.
The withdrawal trials — STEP-4 and SURMOUNT-4 — established what happens when treatment stops entirely. They did not evaluate dose reduction, so the evidence for a lower maintenance dose is inference rather than data.
The caveat is that dose reduction is a clinical decision and this is a description of a search strategy rather than a recommendation.
Going back up after a short gap does not require re-titrating from the bottom.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.